Calix ‘should be applauded’ for Q3 beat, says Rosenblatt

Rosenblatt contends that Calix “should be applauded for delivering a small revenue, GM, and operating margin beat” in Q3 despite the inventory and order challenges impacting the industry. The firm, which thinks Calix is “a hugely innovative company with a strong investment thesis, and the stock is attractive here,” keeps a Buy rating on the shares following the company’s Q3 report and Q4 guidance.